研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

子宫肌瘤:新药物靶点和创新治疗策略的当前研究。

Uterine fibroids: current research on novel drug targets and innovative therapeutic strategies.

发表日期:2024 Aug 13
作者: Michal Ciebiera, Jakub Kociuba, Mohamed Ali, Obianuju Sandra Madueke-Laveaux, Qiwei Yang, Monika Bączkowska, Marta Włodarczyk, Natalia Żeber-Lubecka, Elżbieta Zarychta, Ana Corachán, Samar Alkhrait, Vafaei Somayeh, Iana Malasevskaia, Tomasz Łoziński, Piotr Laudański, Robert Spaczynski, Grzegorz Jakiel, Ayman Al-Hendy
来源: EXPERT OPINION ON THERAPEUTIC TARGETS

摘要:

子宫肌瘤是影响女性生殖道的最常见非恶性肿瘤,是一个重大的医学挑战。本文重点介绍了试图确定超滤治疗中新型非激素治疗靶点和策略的最新研究。这篇综述涵盖了天然物质作用的药理学和生物学机制以及微生物组在治疗中的作用的分析。 UF。本研究旨在确定这些化合物在 UF 预防和治疗中的潜在作用。虽然有多种治疗 UF 的方法,但用于疾病控制的可用药物疗法尚未优化。本综述强调了维生素 D、EGCG 和其他天然化合物以及微生物组作为 UF 管理和预防的有希望的替代方案的生物潜力。尽管这些物质在该领域已得到很好的分析,但我们仍然建议在这些化合物或益生菌的治疗领域进行进一步的研究,特别是随机研究。或者,随着数据质量的不断提高,我们建议考虑将其纳入临床实践,以符合患者的偏好和同意。
Uterine fibroids, the most common nonmalignant tumors affecting the female genital tract, are a significant medical challenge. This article focuses on the most recent studies that attempted to identify novel non-hormonal therapeutic targets and strategies in UF therapy.This review covers the analysis of the pharmacological and biological mechanisms of the action of natural substances and the role of the microbiome in reference to UFs. This study aimed to determine the potential role of these compounds in UF prevention and therapy.While there are numerous approaches for treating UFs, available drug therapies for disease control have not been optimized yet. This review highlights the biological potential of vitamin D, EGCG and other natural compounds, as well as the microbiome, as promising alternatives in UF management and prevention. Although these substances have been quite well analyzed in this area, we still recommend conducting further studies, particularly randomized ones, in the field of therapy with these compounds or probiotics. Alternatively, as the quality of data continues to improve, we propose the consideration of their integration into clinical practice, in alignment with the patient's preferences and consent.